Safety of the EnvPro HIV Vaccine in Healthy Volunteers

Completed · Phase 1

Conditions studied: HIV Infections

In brief

The purpose of this study is to determine the safety of a new HIV vaccine. The vaccine in this study is mixed with a chemical called alum to improve the body's response to the vaccine. Healthy adults who are not infected with HIV may participate in the study.

Key facts

Study ID

NCT00076947

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

10

Starts

2003-08-01

Last updated by the study team

2008-03-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• HIV uninfected
• Normal medical history and physical exam
• Normal complete blood count
• Normal liver function
• Normal renal function
• Normal serum creatine phosphokinase (CPK)
• Availability for at least 1 year follow-up

You may not qualify if…

• History of immunosuppressive illness, chronic illness, or use of any immunosuppressive medications
• Medical or psychiatric condition or occupational responsibilities which preclude compliance with the study
• Live attenuated vaccines within 60 days of study entry
• Use of experimental agents within 30 days of study entry

Where it is running

• St. Jude Children's Research Hospital — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.